Risk of ipsilateral and contralateral cancer in BRCA mutation carriers with breast cancer

被引：3
|
作者：
Green L. [1 ]
Meric-Bernstam F. [1 ]
机构：
[1] Department of Surgical Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030
来源：
Current Breast Cancer Reports | 2011年 / 3卷 / 3期
关键词：
BRCA1; BRCA2; Contralateral breast cancer; Prophylactic mastectomy;
D O I：
10.1007/s12609-011-0047-3
中图分类号：
学科分类号：
摘要：
BRCA1 and BRCA2 mutation carriers with breast cancer have a high risk of ipsilateral breast cancer tumor recurrence (IBTR) and a high lifetime risk of contralateral breast cancer (CBC). The IBTR risk is significantly higher in women who elect breast conservation. Oophorectomy has a protective effect for both ipsilateral breast tumor recurrence and CBC. Patients with younger age of breast cancer onset have a significantly greater risk of CBC. Given the higher risk of IBTR and CBC, when indicated, patients with breast cancer should undergo genetic counseling early in their treatment course to assist them in their surgical decision-making. Knowledge of expected outcomes for BRCA1/2 mutation carriers following breast cancer treatment can help in appropriately counseling patients and personalizing cancer therapy. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：151 / 155
页数：4
相关论文
共 50 条
  • [21] Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Metcalfe, K.
    Gershman, S.
    Lynch, H. T.
    Ghadirian, P.
    Tung, N.
    Kim-Sing, C.
    Olopade, O. I.
    Domchek, S.
    McLennan, J.
    Eisen, A.
    Foulkes, W. D.
    Rosen, B.
    Sun, P.
    Narod, S. A.
    BRITISH JOURNAL OF CANCER, 2011, 104 (09) : 1384 - 1392
  • [22] Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Ahmed, M.
    Lalloo, F.
    Howell, A.
    Evans, D. G.
    BREAST CANCER RESEARCH, 2010, 12 : S6 - S6
  • [23] Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients
    Su, Liming
    Xu, Ye
    Ouyang, Tao
    Li, Jinfeng
    Wang, Tianfeng
    Fan, Zhaoqing
    Fan, Tie
    Lin, Benyao
    Xie, Yuntao
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (12) : 3335 - 3342
  • [24] Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Gronwald, Jacek
    Robidoux, Andre
    Kim-Sing, Charmaine
    Tung, Nadine
    Lynch, Henry T.
    Foulkes, William D.
    Manoukian, Siranoush
    Ainsworth, Peter
    Neuhausen, Susan L.
    Demsky, Rochelle
    Eisen, Andrea
    Singer, Christian F.
    Saal, Howard
    Senter, Leigha
    Eng, Charis
    Weitzel, Jeffrey
    Moller, Pal
    Gilchrist, Dawna M.
    Olopade, Olufunmilayo
    Ginsburg, Ophira
    Sun, Ping
    Huzarski, Tomasz
    Lubinski, Jan
    Narod, Steven A.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (02) : 421 - 427
  • [25] Risk of primary and contralateral breast cancer in BRCA1/2 mutation carriers previously affected with ovarian cancer
    Heemskerk-Gerritsen, B. A. M.
    Hooning, M. J.
    van Doorn, H. C.
    Collee, M.
    Koppert, L. B.
    Jager, A.
    van den Ouweland, A. M. W.
    Seynaeve, C.
    Kriege, M.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 528 - 528
  • [26] BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers
    Sun, Jie
    Chu, Futao
    Pan, Jiani
    Zhang, Yaxin
    Yao, Lu
    Chen, Jiuan
    Hu, Li
    Zhang, Juan
    Xu, Ye
    Wang, Xiaojia
    Cao, Wenming
    Xie, Yuntao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (05) : 991 - +
  • [27] Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Jacek Gronwald
    Andre Robidoux
    Charmaine Kim-Sing
    Nadine Tung
    Henry T. Lynch
    William D. Foulkes
    Siranoush Manoukian
    Peter Ainsworth
    Susan L. Neuhausen
    Rochelle Demsky
    Andrea Eisen
    Christian F. Singer
    Howard Saal
    Leigha Senter
    Charis Eng
    Jeffrey Weitzel
    Pal Moller
    Dawna M. Gilchrist
    Olufunmilayo Olopade
    Ophira Ginsburg
    Ping Sun
    Tomasz Huzarski
    Jan Lubinski
    Steven A. Narod
    Breast Cancer Research and Treatment, 2014, 146 : 421 - 427
  • [28] Risk of primary and contralateral breast cancer in BRCA1/2 mutation carriers previously affected with ovarian cancer
    Heemskerk-Gerritsen, B. A. M.
    Hooning, M. J.
    van Doorn, H. C.
    Collee, M. J.
    Koppert, L. B.
    Jager, A.
    van den Ouweland, A. M. W.
    Netherlands, H.
    Seynaeve, C.
    Kriege, M.
    CANCER RESEARCH, 2017, 77
  • [29] Radiation exposure and breast cancer risk for BRCA mutation carriers
    Goldfrank, DJ
    Chuai, S
    Cajal, TRY
    Lee, JB
    Alonso, MC
    Diez, O
    Baiget, M
    Kauff, ND
    Offit, K
    Bernstein, JL
    Robson, ME
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S23 - S23
  • [30] Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
    van Sprundel, TC
    Schmidt, MK
    Rookus, MA
    Brohet, R
    van Asperen, CJ
    Rutgers, EJT
    van't Veer, L
    Tollenaar, RAEM
    BRITISH JOURNAL OF CANCER, 2005, 93 (03) : 287 - 292
12345